• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胰岛素浓度增加五倍会延迟皮下注射的人胰岛素混悬液在猪体内的吸收。

Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigs.

作者信息

Jørgensen K H, Hansen A K, Buschard K

机构信息

Bartholin Instituttet, Kommunehospitalet, DK-1399, Copenhagen, Denmark.

出版信息

Diabetes Res Clin Pract. 2000 Dec;50(3):161-7. doi: 10.1016/s0168-8227(00)00196-0.

DOI:10.1016/s0168-8227(00)00196-0
PMID:11106830
Abstract

Human NPH U100 (100 IU/ml), given once daily, is often absorbed too fast to cover the basal insulin demand throughout 24 h. The aim of the present study was to examine whether the absorption of human insulin suspensions would be delayed by increasing the insulin concentration from U100 to U500. In each experiment 10 IU of corresponding human Ul00 and U500 preparations, labelled with 125I-insulin, were injected subcutaneously and contralaterally in the neck of a pig followed by monitoring residual radioactivity over the injection sites. The time until 75, 50 and 25% residual radioactivity (T(75%), T(50%) and T(25%)) using NPH U500 was compared with NPH U100 in 14 experiments: T(75%): 5.0+/-0.5 (mean+/-SEM) vs 3.8+/-0.3 h (P=0.007, paired t-test), T(50%): 12. 2+/-0.9 vs 9.0+/-0.6 h (P=0.003) and T(25%). 24.2+/-1.2 vs 17.9+/-1. 2 h (P=0.001). The corresponding values for semilente U500 compared with semilente U100 in eight experiments were: T(75%): 2.8+/-0.4 vs 1.6+/-0.2 h (P=0.02), T(50%): 5.6+/-0.6 vs 3.4+/-0.3 h (P=0.01) and T(25%): 10.9+/-1.1 vs 7.2+/-0.7 h (P=0.009). Thus, the absorption of a given dose of human NPH or human semilente insulin in pigs is substantially delayed by changing the insulin concentration from Ul00 to U500. Human NPH U500 appears to be more appropriate than human NPH U100 for injection once daily in basal insulin therapy.

摘要

人中性鱼精蛋白锌胰岛素U100(100IU/ml),每日注射一次,其吸收往往过快,无法满足24小时的基础胰岛素需求。本研究的目的是检验将胰岛素浓度从U100提高到U500是否会延迟人胰岛素混悬液的吸收。在每个实验中,将10IU相应的人U100和U500制剂,用125I标记胰岛素,皮下注射到猪颈部的对侧,然后监测注射部位的残留放射性。在14个实验中,比较了使用NPH U500与NPH U100时达到75%、50%和25%残留放射性的时间(T(75%)、T(50%)和T(25%)):T(75%):5.0±0.5(平均值±标准误)对3.8±0.3小时(P=0.007,配对t检验),T(50%):12.2±0.9对9.0±0.6小时(P=0.003),T(25%):24.2±1.2对17.9±1.2小时(P=0.001)。在8个实验中,比较了半慢胰岛素U500与半慢胰岛素U100的相应值:T(75%):2.8±0.4对1.6±0.2小时(P=0.02),T(50%):5.6±0.6对3.4±0.3小时(P=0.01),T(25%):10.9±1.1对7.2±0.7小时(P=0.009)。因此,通过将胰岛素浓度从U100改为U500,猪体内给定剂量的人中性鱼精蛋白锌胰岛素或人半慢胰岛素的吸收会显著延迟。人中性鱼精蛋白锌胰岛素U500似乎比人中性鱼精蛋白锌胰岛素U100更适合在基础胰岛素治疗中每日注射一次。

相似文献

1
Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigs.胰岛素浓度增加五倍会延迟皮下注射的人胰岛素混悬液在猪体内的吸收。
Diabetes Res Clin Pract. 2000 Dec;50(3):161-7. doi: 10.1016/s0168-8227(00)00196-0.
2
Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.健康男性中125I标记的甘精胰岛素(HOE 901)的药代动力学:与中性鱼精蛋白锌胰岛素比较及不同皮下注射部位的影响
Diabetes Care. 2000 Jun;23(6):813-9. doi: 10.2337/diacare.23.6.813.
3
Absorption kinetics of regular, isophane, and protamine zinc insulin in normal cats.普通猫体内正规胰岛素、低精蛋白胰岛素和精蛋白锌胰岛素的吸收动力学
Domest Anim Endocrinol. 1990 Oct;7(4):509-15. doi: 10.1016/0739-7240(90)90008-n.
4
Dose-dependent subcutaneous absorption of porcine, bovine and human NPH insulins.
Acta Med Scand. 1984;215(1):69-73. doi: 10.1111/j.0954-6820.1984.tb04971.x.
5
Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.皮下注射长效人胰岛素类似物甘精胰岛素、中性精蛋白锌胰岛素和超长效人胰岛素以及持续皮下输注赖脯胰岛素的药代动力学和药效学
Diabetes. 2000 Dec;49(12):2142-8. doi: 10.2337/diabetes.49.12.2142.
6
Morphology of palpably abnormal injection sites and effects on absorption of isophane(NPH) insulin.可触及异常注射部位的形态及其对低精蛋白锌(NPH)胰岛素吸收的影响。
Diabet Med. 1990 Nov;7(9):795-9. doi: 10.1111/j.1464-5491.1990.tb01494.x.
7
Absorption of NPH (isophane) insulin in resting diabetic patients: evidence for subcutaneous injection in the thigh as the preferred site.精蛋白锌胰岛素(低精蛋白锌胰岛素)在静息糖尿病患者中的吸收:大腿皮下注射作为首选部位的证据。
Diabet Med. 1991 Jun;8(5):453-7. doi: 10.1111/j.1464-5491.1991.tb01631.x.
8
Effect of major surgery on absorption rate of NPH insulin injected s.c.大手术对皮下注射中效胰岛素吸收速率的影响
Br J Anaesth. 1990 Jun;64(6):741-2. doi: 10.1093/bja/64.6.741.
9
Absorption kinetics of short- and intermediate-acting insulins after jet injection with Medi-Jector II.
Diabetes Care. 1988 Oct;11(9):739-42. doi: 10.2337/diacare.11.9.739.
10
Exercise augments the absorption of isophane (NPH) insulin.运动可增强低精蛋白胰岛素(NPH胰岛素)的吸收。
Diabet Med. 1989 May-Jun;6(4):342-5. doi: 10.1111/j.1464-5491.1989.tb01177.x.

引用本文的文献

1
New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).在接受口服降糖药物治疗的初治2型糖尿病患者中,新型300U/ml甘精胰岛素与100U/ml甘精胰岛素的比较:一项随机对照试验(第3版)
Diabetes Obes Metab. 2015 Apr;17(4):386-94. doi: 10.1111/dom.12438. Epub 2015 Feb 12.
2
Application of PK/PD modeling and simulation to dosing regimen optimization of high-dose human regular U-500 insulin.药代动力学/药效学(PK/PD)建模与模拟在高剂量人常规U-500胰岛素给药方案优化中的应用。
J Diabetes Sci Technol. 2014 Jul;8(4):821-9. doi: 10.1177/1932296814532326. Epub 2014 May 12.
3
Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects.
高剂量人用常规 U-500 胰岛素与健康肥胖受试者中用人用常规 U-100 胰岛素的药代动力学和药效学比较。
Diabetes Care. 2011 Dec;34(12):2496-501. doi: 10.2337/dc11-0721. Epub 2011 Oct 12.
4
Extreme insulin resistance: indications and approaches to the use of U-500 insulin in type 2 diabetes mellitus.极度胰岛素抵抗:在 2 型糖尿病中使用 U-500 胰岛素的适应证和方法。
Curr Diab Rep. 2011 Apr;11(2):77-82. doi: 10.1007/s11892-010-0167-6.